Identification

Name
Hydrochlorothiazide
Accession Number
DB00999  (APRD00092)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It has been used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism. [PubChem]

Structure
Thumb
Synonyms
  • HCTZ
External IDs
NSC-53477 / SU-5879
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ava-hydrochlorothiazideTablet25 mgOralAvanstra Inc2011-10-112014-08-21Canada
Ava-hydrochlorothiazideTablet50 mgOralAvanstra Inc2011-10-112014-08-21Canada
Ava-hydrochlorothiazideTablet12.5 mgOralAvanstra Inc2011-10-112014-08-21Canada
Bio-hydrochlorothiazideTablet100 mgOralBiomed PharmaNot applicableNot applicableCanada
Bio-hydrochlorothiazideTablet50 mgOralBiomed Pharma2003-04-11Not applicableCanada
Bio-hydrochlorothiazideTablet25 mgOralBiomed Pharma2003-04-11Not applicableCanada
Diuchlor H Tab 50mgTablet50 mgOralMedic Laboratory LtÉe1964-12-311996-09-09Canada
Dom-hydrochlorothiazideTablet50 mgOralBiomed Pharma2004-02-062013-08-02Canada
Dom-hydrochlorothiazideTablet25 mgOralBiomed Pharma2004-02-062013-08-02Canada
Dom-hydrochlorothiazideTablet12.5 mgOralDominion Pharmacal2006-08-022007-11-02Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Hydro Tab 100mgTablet100 mgOralApotex Corporation1988-12-31Not applicableCanada
Apo Hydro Tab 25mgTablet25 mgOralApotex Corporation1975-12-31Not applicableCanada
Apo Hydro Tab 50mgTablet50 mgOralApotex Corporation1974-12-31Not applicableCanada
Apo-hydroTablet12.5 mgOralApotex Corporation2009-07-02Not applicableCanada
HydrochlorothiazideTablet25 mg/1OralMc Kesson Packaging Services A Buisness Unit Of Mc Kesson Corporation2002-03-29Not applicableUs
HydrochlorothiazideCapsule, gelatin coated12.5 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
HydrochlorothiazideTablet50 mg/1OralQualitest2002-03-292018-09-22Us
HydrochlorothiazideTablet25 mg/1OralContract Pharmacy Services Pa2010-11-09Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralCitron Pharma LLC2007-09-19Not applicableUs
HydrochlorothiazideTablet12.5 mg/1OralAccord Healthcare Limited2013-01-15Not applicableUs
International/Other Brands
Dichlotride (M & H) / Esidrex (Novartis) / Esidrix / Hydrodiuril (Merck) / HydroDIURIL (Merck) / Microzide
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Accel-candesartan/hctzHydrochlorothiazide (12.5 mg) + Candesartan cilexetil (32 mg)TabletOralAccel Pharma IncNot applicableNot applicableCanada
Accel-candesartan/hctzHydrochlorothiazide (25 mg) + Candesartan cilexetil (32 mg)TabletOralAccel Pharma IncNot applicableNot applicableCanada
Accel-candesartan/hctzHydrochlorothiazide (12.5 mg) + Candesartan cilexetil (16 mg)TabletOralAccel Pharma IncNot applicableNot applicableCanada
AccureticHydrochlorothiazide (12.5 mg/1) + Quinapril Hydrochloride (20 mg/1)Tablet, film coatedOralParke Davis Div Of Pfizer Inc1999-12-28Not applicableUs
AccureticHydrochlorothiazide (12.5 mg/1) + Quinapril Hydrochloride (10 mg/1)Tablet, film coatedOralParke Davis Div Of Pfizer Inc1999-12-28Not applicableUs
AccureticHydrochlorothiazide (25 mg/1) + Quinapril Hydrochloride (20 mg/1)Tablet, film coatedOralParke Davis Div Of Pfizer Inc1999-12-28Not applicableUs
Accuretic 10/12.5 mgHydrochlorothiazide (12.5 mg) + Quinapril (10 mg)TabletOralPfizer1998-10-01Not applicableCanada
Accuretic 20/12.5 mgHydrochlorothiazide (12.5 mg) + Quinapril (20 mg)TabletOralPfizer1998-10-01Not applicableCanada
Accuretic 20/25 mgHydrochlorothiazide (25 mg) + Quinapril (20 mg)TabletOralPfizer2003-06-02Not applicableCanada
Ach-olmesartan HctzHydrochlorothiazide (12.5 mg) + Olmesartan medoxomil (20 mg)TabletOralAccord Healthcare LimitedNot applicableNot applicableCanada
Categories
UNII
0J48LPH2TH
CAS number
58-93-5
Weight
Average: 297.739
Monoisotopic: 296.964474846
Chemical Formula
C7H8ClN3O4S2
InChI Key
JZUFKLXOESDKRF-UHFFFAOYSA-N
InChI
InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)
IUPAC Name
6-chloro-1,1-dioxo-3,4-dihydro-2H-1λ⁶,2,4-benzothiadiazine-7-sulfonamide
SMILES
NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1

Pharmacology

Indication

For the treatment of high blood pressure and management of edema.

Structured Indications
Pharmacodynamics

Thiazides such as hydrochlorothiazide promote water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.

Mechanism of action

Hydrochlorothiazide, a thiazide diuretic, inhibits water reabsorption in the nephron by inhibiting the sodium-chloride symporter (SLC12A3) in the distal convoluted tubule, which is responsible for 5% of total sodium reabsorption. Normally, the sodium-chloride symporter transports sodium and chloride from the lumen into the epithelial cell lining the distal convoluted tubule. The energy for this is provided by a sodium gradient established by sodium-potassium ATPases on the basolateral membrane. Once sodium has entered the cell, it is transported out into the basolateral interstitium via the sodium-potassium ATPase, causing an increase in the osmolarity of the interstitium, thereby establishing an osmotic gradient for water reabsorption. By blocking the sodium-chloride symporter, hydrochlorothiazide effectively reduces the osmotic gradient and water reabsorption throughout the nephron.

TargetActionsOrganism
ASolute carrier family 12 member 3
inhibitor
Human
UCarbonic anhydrase 1
inhibitor
Human
UCarbonic anhydrase 2
inhibitor
Human
UCarbonic anhydrase 4
inhibitor
Human
UCarbonic anhydrase 9
inhibitor
Human
UCarbonic anhydrase 12
inhibitor
Human
UCalcium-activated potassium channel subunit alpha-1
other/unknown
Human
Absorption

50-60%

Volume of distribution
Not Available
Protein binding

67.9%

Metabolism

Hydrochlorothiazide is not metabolized.

Route of elimination

Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.

Half life

5.6 and 14.8 hours

Clearance
Not Available
Toxicity

The most common signs and symptoms observed are those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias. The oral LD50 of hydrochlorothiazide is greater than 10 g/kg in the mouse and rat.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Hydrochlorothiazide Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Hydrochlorothiazide.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Hydrochlorothiazide.Experimental, Illicit
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Hydrochlorothiazide.Investigational
5-androstenedione5-androstenedione may increase the hypokalemic activities of Hydrochlorothiazide.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Hydrochlorothiazide.Experimental
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Acebutolol.Approved
AceclofenacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Aceclofenac.Approved, Investigational
AcemetacinThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Acemetacin.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Hydrochlorothiazide.Investigational, Withdrawn
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Acetyldigitoxin.Approved
AcetyldigoxinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Acetyldigoxin.Experimental
Acetylsalicylic acidThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AclidiniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Aclidinium.Approved
AdapaleneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Adapalene.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Hydrochlorothiazide.Experimental, Investigational
AlaproclateAlaproclate may increase the hyponatremic activities of Hydrochlorothiazide.Experimental
AlclofenacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlclometasoneAlclometasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
AlcuroniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Alcuronium.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Hydrochlorothiazide.Approved
AldosteroneAldosterone may increase the hypokalemic activities of Hydrochlorothiazide.Experimental, Investigational
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Hydrochlorothiazide.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Aliskiren.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Hydrochlorothiazide.Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Hydrochlorothiazide.Approved
AlminoprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Alminoprofen.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Hydrochlorothiazide.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Hydrochlorothiazide.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Hydrochlorothiazide.Illicit
AlprenololAlprenolol may increase the hypotensive activities of Hydrochlorothiazide.Approved, Withdrawn
AmbrisentanHydrochlorothiazide may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmcinonideAmcinonide may increase the hypokalemic activities of Hydrochlorothiazide.Approved
AmifostineHydrochlorothiazide may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Hydrochlorothiazide.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Hydrochlorothiazide.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Hydrochlorothiazide.Approved
AmobarbitalAmobarbital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved, Illicit
AmphetamineAmphetamine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Hydrochlorothiazide.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Amyl Nitrite.Approved
AndrographolideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Andrographolide.Investigational
AndrostenedioneAndrostenedione may increase the hypokalemic activities of Hydrochlorothiazide.Experimental, Illicit
AnecortaveAnecortave may increase the hypokalemic activities of Hydrochlorothiazide.Investigational
anecortave acetateanecortave acetate may increase the hypokalemic activities of Hydrochlorothiazide.Investigational
AnisodamineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Anisodamine.Investigational
Anisotropine MethylbromideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Anisotropine Methylbromide.Approved
AntipyrineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Antipyrine.Approved
ApocyninThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Apocynin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Hydrochlorothiazide.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Hydrochlorothiazide.Approved
ApremilastThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Apremilast.Approved, Investigational
ArbutamineArbutamine may increase the hypokalemic activities of Hydrochlorothiazide.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Hydrochlorothiazide.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Hydrochlorothiazide.Approved, Investigational
AtamestaneAtamestane may increase the hypokalemic activities of Hydrochlorothiazide.Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Hydrochlorothiazide.Approved
AtracuriumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Atracurium.Experimental, Investigational
Atracurium besylateThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Atracurium besylate.Approved
AtropineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Atropine.Approved, Vet Approved
AvanafilAvanafil may increase the antihypertensive activities of Hydrochlorothiazide.Approved
AzapropazoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Azilsartan medoxomil.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Hydrochlorothiazide.Investigational
BalsalazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Balsalazide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Experimental
BarbitalBarbital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Hydrochlorothiazide.Approved
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Hydrochlorothiazide.Investigational
BenactyzineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Benactyzine.Withdrawn
BenazeprilHydrochlorothiazide may increase the hypotensive activities of Benazepril.Approved, Investigational
BendazacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Bendazac.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Hydrochlorothiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
BenorilateThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzatropineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Benzatropine.Approved
BenzydamineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Benzydamine.Approved
BepridilHydrochlorothiazide may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetamethasoneBetamethasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Hydrochlorothiazide.Approved
BethanidineBethanidine may increase the hypotensive activities of Hydrochlorothiazide.Approved
BevoniumThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Bevonium.Experimental
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Hydrochlorothiazide.Experimental, Illicit, Withdrawn
BietaserpineBietaserpine may increase the hypotensive activities of Hydrochlorothiazide.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
BiperidenThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Biperiden.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Hydrochlorothiazide.Approved
BornaprineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Bornaprine.Experimental
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Hydrochlorothiazide.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
BQ-123Hydrochlorothiazide may increase the hypotensive activities of BQ-123.Investigational
BretyliumThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Hydrochlorothiazide.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Hydrochlorothiazide.Experimental
BromfenacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Hydrochlorothiazide.Approved, Investigational
BucillamineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Bucillamine.Investigational
BudesonideBudesonide may increase the hypokalemic activities of Hydrochlorothiazide.Approved
BufexamacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Bufexamac.Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Hydrochlorothiazide.Investigational, Withdrawn
BumadizoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Hydrochlorothiazide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Hydrochlorothiazide.Approved, Investigational
BupranololHydrochlorothiazide may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Hydrochlorothiazide.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Hydrochlorothiazide.Approved, Illicit, Vet Approved
CadralazineCadralazine may increase the hypotensive activities of Hydrochlorothiazide.Experimental
CafedrineHydrochlorothiazide may increase the hypotensive activities of Cafedrine.Investigational
CalcidiolHydrochlorothiazide may increase the hypercalcemic activities of Calcidiol.Approved, Nutraceutical
CalcipotriolHydrochlorothiazide may increase the hypercalcemic activities of Calcipotriol.Approved
Calcium AcetateHydrochlorothiazide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
Calcium CarbonateHydrochlorothiazide may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved
Calcium ChlorideHydrochlorothiazide may decrease the excretion rate of Calcium Chloride which could result in a higher serum level.Approved
Calcium CitrateHydrochlorothiazide may decrease the excretion rate of Calcium Citrate which could result in a higher serum level.Approved
Calcium glubionateHydrochlorothiazide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved
Calcium GluceptateHydrochlorothiazide may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Approved
Calcium gluconateHydrochlorothiazide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved, Vet Approved
Calcium lactateHydrochlorothiazide may decrease the excretion rate of Calcium lactate which could result in a higher serum level.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateHydrochlorothiazide may decrease the excretion rate of Calcium lactate gluconate which could result in a higher serum level.Experimental
Calcium laevulateHydrochlorothiazide may decrease the excretion rate of Calcium laevulate which could result in a higher serum level.Experimental
Calcium pangamateHydrochlorothiazide may decrease the excretion rate of Calcium pangamate which could result in a higher serum level.Experimental
Calcium PhosphateHydrochlorothiazide may decrease the excretion rate of Calcium Phosphate which could result in a higher serum level.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Canagliflozin.Approved
CandesartanHydrochlorothiazide may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Hydrochlorothiazide.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Hydrochlorothiazide.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Hydrochlorothiazide.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Hydrochlorothiazide.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Hydrochlorothiazide.Illicit, Investigational, Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
CarprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Hydrochlorothiazide.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Carvedilol.Approved, Investigational
CaseinHydrochlorothiazide may decrease the excretion rate of Casein which could result in a higher serum level.Approved
CastanospermineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
ChloroquineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Hydrochlorothiazide.Approved, Vet Approved
ChlorphenoxamineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Chlorphenoxamine.Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Hydrochlorothiazide.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Hydrochlorothiazide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Hydrochlorothiazide.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Hydrochlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
CicletanineHydrochlorothiazide may increase the hypotensive activities of Cicletanine.Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Hydrochlorothiazide.Experimental
CilazaprilThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Hydrochlorothiazide.Approved, Investigational
CitalopramCitalopram may increase the hyponatremic activities of Hydrochlorothiazide.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Clevidipine.Approved
ClobetasolClobetasol may increase the hypokalemic activities of Hydrochlorothiazide.Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Hydrochlorothiazide.Approved
ClobetasoneClobetasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Hydrochlorothiazide.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Hydrochlorothiazide.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Hydrochlorothiazide.Approved
ClonixinThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Clonixin.Approved
CloranololHydrochlorothiazide may increase the hypotensive activities of Cloranolol.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Hydrochlorothiazide.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Hydrochlorothiazide.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Hydrochlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Hydrochlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Hydrochlorothiazide.Approved, Investigational
Cortexolone 17α-propionateCortexolone 17α-propionate may increase the hypokalemic activities of Hydrochlorothiazide.Investigational
CorticosteroneCorticosterone may increase the hypokalemic activities of Hydrochlorothiazide.Experimental
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Hydrochlorothiazide.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Hydrochlorothiazide.Approved
CurcuminThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Curcumin.Investigational
CyclopenthiazideHydrochlorothiazide may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclopentolateThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Cyclopentolate.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Cyclophosphamide.Approved, Investigational
CyclothiazideCyclothiazide may increase the hypotensive activities of Hydrochlorothiazide.Approved
CymarinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Cymarin.Experimental
D-LimoneneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with D-Limonene.Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the hyponatremic activities of Hydrochlorothiazide.Investigational
DarifenacinThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Darifenacin.Approved, Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
DeflazacortDeflazacort may increase the hypokalemic activities of Hydrochlorothiazide.Approved
DelaprilHydrochlorothiazide may increase the hypotensive activities of Delapril.Experimental
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Hydrochlorothiazide.Investigational
DeserpidineHydrochlorothiazide may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Hydrochlorothiazide.Approved
DeslanosideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Deslanoside.Approved
DesloratadineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Desloratadine.Approved, Investigational
DesonideDesonide may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Hydrochlorothiazide.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Hydrochlorothiazide.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the hyponatremic activities of Hydrochlorothiazide.Approved
DexamethasoneDexamethasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Hydrochlorothiazide.Vet Approved
DexetimideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Dexetimide.Withdrawn
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Hydrochlorothiazide.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Hydrochlorothiazide.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Hydrochlorothiazide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Hydrochlorothiazide.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Hydrochlorothiazide.Approved, Investigational
DiazoxideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Diazoxide.Approved
DiclofenacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Diclofenamide.Approved
DicyclomineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Dicyclomine.Approved
diethylnorspermineHydrochlorothiazide may increase the hypotensive activities of diethylnorspermine.Investigational
DifenpiramideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Difenpiramide.Experimental
DiflorasoneDiflorasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
DiflunisalThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Diflunisal.Approved
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
DifluprednateDifluprednate may increase the hypokalemic activities of Hydrochlorothiazide.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digitoxin.Approved, Investigational
DigoxinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digoxin.Approved
Digoxin Immune Fab (Ovine)The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digoxin Immune Fab (Ovine).Approved
DihydralazineDihydralazine may increase the hypotensive activities of Hydrochlorothiazide.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Hydrochlorothiazide.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Hydrochlorothiazide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Hydrochlorothiazide.Experimental, Illicit
DihydrotachysterolHydrochlorothiazide may increase the hypercalcemic activities of Dihydrotachysterol.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Hydrochlorothiazide.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Dinutuximab.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Hydrochlorothiazide.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Hydrochlorothiazide.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Hydrochlorothiazide.Approved
DobutamineDobutamine may increase the hypokalemic activities of Hydrochlorothiazide.Approved
DofetilideHydrochlorothiazide may increase the QTc-prolonging activities of Dofetilide.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Hydrochlorothiazide.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Hydrochlorothiazide.Approved
DoxercalciferolHydrochlorothiazide may increase the hypercalcemic activities of Doxercalciferol.Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Hydrochlorothiazide.Investigational
DroxicamThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Droxicam.Approved
DroxidopaDroxidopa may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Hydrochlorothiazide.Approved
DuloxetineHydrochlorothiazide may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Duvelisib.Investigational
E-6201The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with E-6201.Investigational
EfonidipineHydrochlorothiazide may increase the hypotensive activities of Efonidipine.Approved, Investigational
EmeproniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Emepronium.Experimental
EmpagliflozinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Hydrochlorothiazide.Approved, Vet Approved
EnalaprilatHydrochlorothiazide may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Hydrochlorothiazide.Experimental
EpanololHydrochlorothiazide may increase the hypotensive activities of Epanolol.Experimental
EphedraEphedra may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
EpirizoleThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Epirizole.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Hydrochlorothiazide.Approved
EpoprostenolHydrochlorothiazide may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Hydrochlorothiazide.Approved
EquileninEquilenin may increase the hypokalemic activities of Hydrochlorothiazide.Experimental
EquilinEquilin may increase the hypokalemic activities of Hydrochlorothiazide.Approved
ErgocalciferolHydrochlorothiazide may increase the hypercalcemic activities of Ergocalciferol.Approved, Nutraceutical
EscitalopramEscitalopram may increase the hyponatremic activities of Hydrochlorothiazide.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Hydrochlorothiazide.Approved
EstroneEstrone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Hydrochlorothiazide.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Hydrochlorothiazide.Approved
EtanautineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Etanautine.Experimental
EtanerceptThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Etanercept.Approved, Investigational
EthanolEthanol may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved
EthenzamideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Ethenzamide.Experimental
EthopropazineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Ethopropazine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Hydrochlorothiazide.Approved, Illicit
EtodolacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Etofenamate.Approved, Investigational
EtoperidoneEtoperidone may increase the hyponatremic activities of Hydrochlorothiazide.Withdrawn
EtoricoxibThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Hydrochlorothiazide.Illicit, Vet Approved
EtybenzatropineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Etybenzatropine.Experimental
Evening primrose oilThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Evening primrose oil.Approved, Investigational
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
exisulindThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with exisulind.Investigational
FelbinacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Felbinac.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Felodipine.Approved, Investigational
FenbufenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Hydrochlorothiazide.Approved
FenoprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Fenoprofen.Approved
FenoterolFenoterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Hydrochlorothiazide.Approved, Illicit, Investigational, Vet Approved
FentiazacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Fentiazac.Experimental
FeprazoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Feprazone.Experimental
Ferulic acidThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Ferulic acid.Experimental
FesoterodineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Fesoterodine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Hydrochlorothiazide.Approved, Investigational
FloctafenineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Floctafenine.Approved, Withdrawn
fluasteronefluasterone may increase the hypokalemic activities of Hydrochlorothiazide.Investigational
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
FlumethasoneFlumethasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
FlunisolideFlunisolide may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
FlunixinThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Flunoxaprofen.Experimental
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
FluoxetineFluoxetine may increase the hyponatremic activities of Hydrochlorothiazide.Approved, Vet Approved
FluprednideneFluprednidene may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Hydrochlorothiazide.Approved
FlurbiprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Flurbiprofen.Approved, Investigational
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Hydrochlorothiazide.Approved
Fluticasone propionateFluticasone propionate may increase the hypokalemic activities of Hydrochlorothiazide.Approved
FluvoxamineFluvoxamine may increase the hyponatremic activities of Hydrochlorothiazide.Approved, Investigational
FormestaneFormestane may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Hydrochlorothiazide.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Hydrochlorothiazide.Approved, Vet Approved
GallamineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Gallamine.Experimental
Gallamine TriethiodideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Gallamine Triethiodide.Approved
GitoformateThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Gitoformate.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Hydrochlorothiazide.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Hydrochlorothiazide.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Hydrochlorothiazide.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Hydrochlorothiazide.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Hydrochlorothiazide.Approved
GlycopyrroniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Glycopyrronium.Approved, Investigational, Vet Approved
GuacetisalThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Hydrochlorothiazide.Approved
GuanazodineHydrochlorothiazide may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineHydrochlorothiazide may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Guanfacine.Approved, Investigational
GuanoclorHydrochlorothiazide may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzHydrochlorothiazide may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanHydrochlorothiazide may increase the hypotensive activities of Guanoxan.Experimental
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Hydrochlorothiazide.Investigational
HalcinonideHalcinonide may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Hydrochlorothiazide.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Hydrochlorothiazide.Experimental
HE3286HE3286 may increase the hypokalemic activities of Hydrochlorothiazide.Investigational
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Hydrochlorothiazide.Approved, Illicit, Investigational
HexamethoniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved
HigenamineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Higenamine.Investigational
HomatropineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Homatropine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Hydrochlorothiazide.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Hydralazine.Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Hydrochlorothiazide.Approved, Illicit
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Hydrochlorothiazide.Approved, Illicit
HyoscyamineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Hyoscyamine.Approved
IbuprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Icatibant.Approved
IloprostIloprost may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Hydrochlorothiazide.Investigational
Imidazole salicylateThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Imidazole salicylate.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Hydrochlorothiazide.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved
IndalpineIndalpine may increase the hyponatremic activities of Hydrochlorothiazide.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Hydrochlorothiazide.Approved
IndenololHydrochlorothiazide may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Hydrochlorothiazide.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Hydrochlorothiazide.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Hydrochlorothiazide.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Hydrochlorothiazide.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Hydrochlorothiazide.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Hydrochlorothiazide.Approved
Ipratropium bromideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Ipratropium bromide.Approved
IproclozideIproclozide may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Hydrochlorothiazide.Approved
IsoetarineIsoetarine may increase the hypokalemic activities of Hydrochlorothiazide.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Hydrochlorothiazide.Approved, Vet Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Hydrochlorothiazide.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Hydrochlorothiazide.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Isosorbide Mononitrate.Approved
IsoxicamThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Hydrochlorothiazide.Approved
IstaroximeIstaroxime may increase the hypokalemic activities of Hydrochlorothiazide.Investigational
IvabradineHydrochlorothiazide may increase the arrhythmogenic activities of Ivabradine.Approved
KebuzoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Hydrochlorothiazide.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Hydrochlorothiazide.Approved, Investigational
KetoprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Hydrochlorothiazide.Approved
LacidipineHydrochlorothiazide may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanatoside CThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Lanatoside C.Experimental
LatanoprostLatanoprost may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
LeflunomideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Hydrochlorothiazide.Approved, Investigational
LevodopaHydrochlorothiazide may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Hydrochlorothiazide.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the hyponatremic activities of Hydrochlorothiazide.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Hydrochlorothiazide.Approved
LevosalbutamolLevosalbutamol may increase the hypokalemic activities of Hydrochlorothiazide.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Hydrochlorothiazide.Approved, Investigational
LicoriceLicorice may increase the hypokalemic activities of Hydrochlorothiazide.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Hydrochlorothiazide.Approved
LinsidomineHydrochlorothiazide may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Hydrochlorothiazide.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Hydrochlorothiazide.Approved, Investigational
LisofyllineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Lisofylline.Investigational
LithiumHydrochlorothiazide may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Hydrochlorothiazide.Illicit
LofexidineHydrochlorothiazide may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Lonazolac.Experimental
LornoxicamThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Hydrochlorothiazide.Approved
LoteprednolLoteprednol may increase the hypokalemic activities of Hydrochlorothiazide.Approved
LoxoprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Loxoprofen.Approved, Investigational
LumiracoxibThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Lumiracoxib.Approved, Investigational
MacitentanHydrochlorothiazide may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Magnesium salicylate.Approved
ManidipineHydrochlorothiazide may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Hydrochlorothiazide.Approved, Investigational
MasoprocolThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Masoprocol.Approved, Investigational
MazaticolThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Mazaticol.Experimental
ME-609ME-609 may increase the hypokalemic activities of Hydrochlorothiazide.Investigational
MebanazineMebanazine may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Mecamylamine.Approved
Meclofenamic acidThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
Mefenamic acidThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Mefenamic acid.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Hydrochlorothiazide.Vet Approved
MeloxicamThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Hydrochlorothiazide.Experimental
MesalazineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Metamizole.Investigational, Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Hydrochlorothiazide.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Hydrochlorothiazide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Hydrochlorothiazide.Approved, Illicit
MethanthelineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Methantheline.Approved, Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Hydrochlorothiazide.Approved
MethohexitalMethohexital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved
MethoserpidineHydrochlorothiazide may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Hydrochlorothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Hydrochlorothiazide.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Hydrochlorothiazide.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
Methylscopolamine bromideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Methylscopolamine bromide.Approved
MetildigoxinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Metildigoxin.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Metipranolol.Approved
MetixeneThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Metixene.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Hydrochlorothiazide.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Hydrochlorothiazide.Approved, Investigational
MetyrosineHydrochlorothiazide may increase the hypotensive activities of Metyrosine.Approved
MibefradilHydrochlorothiazide may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Hydrochlorothiazide.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Hydrochlorothiazide.Approved
MilnacipranMilnacipran may increase the hyponatremic activities of Hydrochlorothiazide.Approved
MinaprineMinaprine may increase the hypotensive activities of Hydrochlorothiazide.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Hydrochlorothiazide.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Hydrochlorothiazide.Investigational
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
MizoribineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Hydrochlorothiazide.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Hydrochlorothiazide.Approved
MofebutazoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
MometasoneMometasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Hydrochlorothiazide.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
MuzolimineHydrochlorothiazide may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Hydrochlorothiazide.Approved, Investigational
NabumetoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Nadolol.Approved
NafamostatThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Nafamostat.Approved, Investigational
NaftifineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Naftifine.Approved
NaftopidilHydrochlorothiazide may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Hydrochlorothiazide.Approved
NaproxenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Naproxen.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
NCX 1022NCX 1022 may increase the hypokalemic activities of Hydrochlorothiazide.Investigational
NebivololThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the hyponatremic activities of Hydrochlorothiazide.Approved, Withdrawn
NepafenacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Hydrochlorothiazide.Approved
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Hydrochlorothiazide.Experimental
NicorandilNicorandil may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Nifedipine.Approved
NifenazoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Niflumic Acid.Approved
NiguldipineHydrochlorothiazide may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineHydrochlorothiazide may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Hydrochlorothiazide.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Hydrochlorothiazide.Approved
NitrendipineHydrochlorothiazide may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Hydrochlorothiazide.Approved
NitroaspirinThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Hydrochlorothiazide.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Hydrochlorothiazide.Approved
NorepinephrineNorepinephrine may increase the hypokalemic activities of Hydrochlorothiazide.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Hydrochlorothiazide.Approved, Illicit
ObinutuzumabHydrochlorothiazide may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
OleandrinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Oleandrin.Experimental, Investigational
Oleoyl-estroneOleoyl-estrone may increase the hypokalemic activities of Hydrochlorothiazide.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Hydrochlorothiazide.Approved, Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved
OlopatadineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Olsalazine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Hydrochlorothiazide.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Hydrochlorothiazide.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Hydrochlorothiazide.Approved
OrgoteinThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Orgotein.Vet Approved
OrphenadrineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Orphenadrine.Approved
OtiloniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Otilonium.Experimental, Investigational
OuabainThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Ouabain.Approved
OxaprozinThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Oxaprozin.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Oxcarbazepine.Approved
OxitropiumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Oxitropium.Investigational
OxprenololHydrochlorothiazide may increase the hypotensive activities of Oxprenolol.Approved
OxybutyninThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Hydrochlorothiazide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Hydrochlorothiazide.Approved, Investigational, Vet Approved
OxyphenbutazoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Oxyphenbutazone.Approved, Withdrawn
OxyphenoniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Oxyphenonium.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Hydrochlorothiazide.Approved, Vet Approved
PancuroniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Pancuronium.Approved
PapaverineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Papaverine.Approved
ParamethasoneParamethasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
ParecoxibThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Hydrochlorothiazide.Approved
ParicalcitolHydrochlorothiazide may increase the hypercalcemic activities of Paricalcitol.Approved, Investigational
ParoxetineParoxetine may increase the hyponatremic activities of Hydrochlorothiazide.Approved, Investigational
ParthenolideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Parthenolide.Investigational
PenbutololThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Hydrochlorothiazide.Approved, Vet Approved
PentobarbitalPentobarbital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
PentoliniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Hydrochlorothiazide.Approved
PeruvosideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Hydrochlorothiazide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Hydrochlorothiazide.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Hydrochlorothiazide.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational, Withdrawn
PhenglutarimideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Phenglutarimide.Experimental
PheniprazinePheniprazine may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
PhenobarbitalPhenobarbital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Hydrochlorothiazide.Experimental
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Hydrochlorothiazide.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Hydrochlorothiazide.Approved
PhenylbutazoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved, Withdrawn
PimecrolimusThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Hydrochlorothiazide.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Hydrochlorothiazide.Approved, Investigational
PipecuroniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Pipecuronium.Approved
PirbuterolPirbuterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved
PirenzepineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Pirenzepine.Approved
PirfenidoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Pirfenidone.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Hydrochlorothiazide.Investigational
PirlindolePirlindole may increase the hypotensive activities of Hydrochlorothiazide.Approved
PiroxicamThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Pirprofen.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
Platelet Activating FactorHydrochlorothiazide may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideHydrochlorothiazide may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Hydrochlorothiazide.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
PranoprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Pranoprofen.Experimental, Investigational
PrasteronePrasterone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Nutraceutical
Prasterone sulfatePrasterone sulfate may increase the hypokalemic activities of Hydrochlorothiazide.Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Hydrochlorothiazide.Approved
PrednicarbatePrednicarbate may increase the hypokalemic activities of Hydrochlorothiazide.Approved
PrednisolonePrednisolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Hydrochlorothiazide.Experimental, Investigational
PrimidonePrimidone may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Hydrochlorothiazide.Approved
ProcaterolProcaterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
ProcyclidineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Procyclidine.Approved
ProglumetacinThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Proglumetacin.Experimental
PropacetamolThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Propacetamol.Approved, Investigational
PropanthelineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Propantheline.Approved
PropiverineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Propiverine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Hydrochlorothiazide.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Hydrochlorothiazide.Approved, Investigational
PropyphenazoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Proquazone.Experimental
ProscillaridinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Proscillaridin.Experimental
PTC299The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Hydrochlorothiazide.Approved, Investigational
QuinidineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Hydrochlorothiazide.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Hydrochlorothiazide.Approved
RasagilineRasagiline may increase the hypotensive activities of Hydrochlorothiazide.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Hydrochlorothiazide.Approved
RemikirenRemikiren may increase the hypotensive activities of Hydrochlorothiazide.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
RescinnamineHydrochlorothiazide may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Hydrochlorothiazide.Approved, Investigational
ResveratrolThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Resveratrol.Approved, Experimental, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Hydrochlorothiazide.Investigational
RimexoloneRimexolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
RiociguatThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Riociguat.Approved
RisperidoneHydrochlorothiazide may increase the hypotensive activities of Risperidone.Approved, Investigational
RitodrineRitodrine may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
RituximabHydrochlorothiazide may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Hydrochlorothiazide.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Hydrochlorothiazide.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Hydrochlorothiazide.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Hydrochlorothiazide.Approved
SafrazineSafrazine may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
SalbutamolSalbutamol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
SalicylamideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved
SalsalateThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Salsalate.Approved
SaprisartanHydrochlorothiazide may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Hydrochlorothiazide.Approved
ScopolamineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Scopolamine.Approved
Scopolamine butylbromideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Scopolamine butylbromide.Approved, Vet Approved
SecobarbitalSecobarbital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational, Vet Approved
SelexipagHydrochlorothiazide may increase the hypotensive activities of Selexipag.Approved
SemapimodThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Semapimod.Investigational
SeratrodastThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Seratrodast.Approved
SerrapeptaseThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Serrapeptase.Investigational
SertralineSertraline may increase the hyponatremic activities of Hydrochlorothiazide.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Hydrochlorothiazide.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Hydrochlorothiazide.Approved, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
SitaxentanHydrochlorothiazide may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Hydrochlorothiazide.Approved
Sodium phosphateHydrochlorothiazide may increase the nephrotoxic activities of Sodium phosphate.Approved
SolifenacinThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Solifenacin.Approved
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Hydrochlorothiazide.Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Hydrochlorothiazide.Approved
SpiraprilHydrochlorothiazide may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Hydrochlorothiazide.Approved
SRT501The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Hydrochlorothiazide.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Hydrochlorothiazide.Approved, Investigational
SulfasalazineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Sulindac.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Sulpiride.Approved, Investigational
SuprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Suxibuzone.Experimental
TadalafilTadalafil may increase the antihypertensive activities of Hydrochlorothiazide.Approved, Investigational
TalinololHydrochlorothiazide may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Hydrochlorothiazide.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Hydrochlorothiazide.Approved
TarenflurbilThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tarenflurbil.Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Hydrochlorothiazide.Approved, Investigational
TemocaprilHydrochlorothiazide may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tenidap.Experimental
TenoxicamThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Terazosin.Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Hydrochlorothiazide.Approved
TeriflunomideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Teriflunomide.Approved
TerlipressinHydrochlorothiazide may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineHydrochlorothiazide may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Hydrochlorothiazide.Approved, Investigational, Withdrawn
TheodrenalineHydrochlorothiazide may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThiamylal may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
ThiopentalThiopental may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Hydrochlorothiazide.Approved, Withdrawn
Tiaprofenic acidThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tiaprofenic acid.Approved
TiboloneHydrochlorothiazide may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenHydrochlorothiazide may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Hydrochlorothiazide.Experimental
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Hydrochlorothiazide.Approved
TinoridineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tinoridine.Investigational
TiotropiumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Tiotropium.Approved
TixocortolTixocortol may increase the hypokalemic activities of Hydrochlorothiazide.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Hydrochlorothiazide.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Hydrochlorothiazide.Approved
TolazolineTolazoline may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Hydrochlorothiazide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Hydrochlorothiazide.Approved, Withdrawn
Tolfenamic AcidThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tolfenamic Acid.Approved
TolmetinThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tolmetin.Approved
TolonidineHydrochlorothiazide may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Hydrochlorothiazide.Approved
TolterodineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Tolterodine.Approved, Investigational
TopiramateHydrochlorothiazide may increase the hypokalemic activities of Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Hydrochlorothiazide.Approved
ToremifeneHydrochlorothiazide may increase the hypercalcemic activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Hydrochlorothiazide.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Hydrochlorothiazide.Approved
TranilastThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Hydrochlorothiazide.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Hydrochlorothiazide.Approved
TravoprostTravoprost may increase the hypotensive activities of Hydrochlorothiazide.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Hydrochlorothiazide.Approved, Investigational, Nutraceutical
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Hydrochlorothiazide.Approved
TribenosideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tribenoside.Experimental
TrichlormethiazideHydrochlorothiazide may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrihexyphenidylThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Trihexyphenidyl.Approved
TrimazosinTrimazosin may increase the hypotensive activities of Hydrochlorothiazide.Experimental
TrimethaphanThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Trimethaphan.Approved, Investigational
TriptolideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Triptolide.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Hydrochlorothiazide.Investigational, Withdrawn
TropatepineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Tropatepine.Experimental
TropicamideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Tropicamide.Approved
TrospiumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Trospium.Approved
TubocurarineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Tubocurarine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Hydrochlorothiazide.Approved, Investigational
UlobetasolUlobetasol may increase the hypokalemic activities of Hydrochlorothiazide.Approved
UmeclidiniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Umeclidinium.Approved
UnoprostoneHydrochlorothiazide may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may increase the hypotensive activities of Hydrochlorothiazide.Investigational
ValdecoxibThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Valdecoxib.Investigational, Withdrawn
ValsartanHydrochlorothiazide may increase the hypotensive activities of Valsartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Hydrochlorothiazide.Approved
VecuroniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Vecuronium.Approved
VenlafaxineVenlafaxine may increase the hyponatremic activities of Hydrochlorothiazide.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Hydrochlorothiazide.Approved
VilanterolVilanterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
VincamineHydrochlorothiazide may increase the hypotensive activities of Vincamine.Experimental
VinpocetineHydrochlorothiazide may increase the hypotensive activities of Vinpocetine.Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
XipamideHydrochlorothiazide may increase the hypotensive activities of Xipamide.Experimental
XylometazolineHydrochlorothiazide may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Hydrochlorothiazide.Approved, Vet Approved
ZaltoprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Zaltoprofen.Approved, Investigational
ZileutonThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the hyponatremic activities of Hydrochlorothiazide.Withdrawn
ZofenoprilHydrochlorothiazide may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Zomepirac.Withdrawn
Food Interactions
  • Avoid alcohol.
  • Avoid excess salt/sodium unless otherwise instructed by your physician.
  • Avoid natural licorice.
  • Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication.
  • Increase potassium intake; add a banana or orange juice; unless instructed otherwise.
  • Take with food.

References

Synthesis Reference

Frederic J. Nugent, John K. C. Yen, "Process for preparing the combination products of triamterene and hydrochlorothiazide." U.S. Patent US4804540, issued July, 1987.

US4804540
General References
Not Available
External Links
Human Metabolome Database
HMDB01928
KEGG Drug
D00340
KEGG Compound
C07041
PubChem Compound
3639
PubChem Substance
46504440
ChemSpider
3513
BindingDB
13076
ChEBI
5778
ChEMBL
CHEMBL435
Therapeutic Targets Database
DAP000750
PharmGKB
PA449899
HET
HCZ
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Hydrochlorothiazide
ATC Codes
C09XA52 — Aliskiren and hydrochlorothiazideC09DX03 — Olmesartan medoxomil, amlodipine and hydrochlorothiazideC09DX01 — Valsartan, amlodipine and hydrochlorothiazideC03AB03 — Hydrochlorothiazide and potassiumC03EA01 — Hydrochlorothiazide and potassium-sparing agentsC03AX01 — Hydrochlorothiazide, combinationsC03AA03 — HydrochlorothiazideC09XA54 — Aliskiren, amlodipine and hydrochlorothiazideG01AE10 — Combinations of sulfonamides
AHFS Codes
  • 40:28.20 — Thiazide Diuretics
PDB Entries
3ijx / 3ik6
MSDS
Download (72.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedNot AvailableHealthy Volunteers1
0TerminatedHealth Services ResearchHypertensive / Proteinuria / Type 2 Diabetes Mellitus1
1CompletedNot AvailableHealthy Volunteers10
1CompletedNot AvailableHypertension,Essential2
1CompletedNot AvailableKidney Diseases1
1CompletedTreatmentFasting1
1CompletedTreatmentHealthy Volunteers12
1CompletedTreatmentHypertensive5
1CompletedTreatmentType 2 Diabetes Mellitus2
1Unknown StatusTreatmentHealthy Volunteers1
1, 2RecruitingBasic ScienceHypertension,Essential1
2CompletedBasic ScienceType 2 Diabetes Mellitus1
2CompletedTreatmentAging / Cognitive Impairments / Hypertensive1
2CompletedTreatmentBMI >30 kg/m2 / Hypertensive1
2CompletedTreatmentHypertension,Essential1
2CompletedTreatmentHypertensive3
2CompletedTreatmentHypertensive / Type 2 Diabetes Mellitus1
2CompletedTreatmentMild Hypertension1
2RecruitingTreatmentAutosomal Dominant Hypocalcemia / Autosomal Dominant Hypocalcemia or OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment1
2RecruitingTreatmentBMI >30 kg/m2 / Hypertensive / Prehypertension1
2RecruitingTreatmentHigh Blood Pressure / Hypertensive1
2TerminatedTreatmentHypertensive / Type 2 Diabetes Mellitus1
2TerminatedTreatmentNon-diabetic Nephropathy1
2TerminatedTreatmentPre-Diabetic / Pre-Hypertension1
2WithdrawnTreatmentDiabetes / Hypertensive1
2, 3CompletedTreatmentGrade I or II Essential Hypertension1
2, 3TerminatedTreatmentCalcium Nephrolithiasis / Dent's Disease1
3CompletedNot AvailableCardiovascular Disease (CVD) / Death, Sudden,Cardiac / Heart Arrest / Heart Diseases / Hypertensive1
3CompletedDiagnosticHypertensive1
3CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Hypercholesterolaemia / Hypertensive / Type 2 Diabetes Mellitus1
3CompletedTreatmentAtherosclerotic Cardiovascular Diseases / Hypertension,Essential1
3CompletedTreatmentBlood Pressure, High / Hypertensive1
3CompletedTreatmentChronic Kidney Disease (CKD) / Hypertensive1
3CompletedTreatmentHigh Blood Pressure (Hypertension)1
3CompletedTreatmentHypertension,Essential11
3CompletedTreatmentHypertension; Hypertrophy, Left Ventricular1
3CompletedTreatmentHypertensive33
3CompletedTreatmentHypertensive / Metabolic Disorders1
3CompletedTreatmentHypertensive / Obesity, Abdominal1
3CompletedTreatmentSafety1
3Not Yet RecruitingPreventionGestational Hypertension / Hypertension, Pregnancy-Induced / Postpartum Preeclampsia / Postpartum Pregnancy-Induced Hypertension / Prophylaxis of preeclampsia / Superimposed Pre-Eclampsia1
3Not Yet RecruitingTreatmentArterial Hypertension1
3Not Yet RecruitingTreatmentEssential Arterial Hypertension1
3Not Yet RecruitingTreatmentHypertensive2
3RecruitingPreventionCalcium Nephrolithiasis1
3RecruitingTreatmentHypertensive1
3TerminatedTreatmentCardiovascular Events1
3WithdrawnTreatmentEssential Arterial Hypertension2
4Active Not RecruitingTreatmentObstructive Sleep Apnea (OSA)1
4CompletedDiagnosticHigh Blood Pressure1
4CompletedDiagnosticHypertension,Essential1
4CompletedDiagnosticHypertensive1
4CompletedPreventionNonvalvular Atrial Fibrillation1
4CompletedTreatmentAlbuminuria / Hypertensive / Type 2 Diabetes Mellitus1
4CompletedTreatmentBMI >30 kg/m2 / Hypertensive1
4CompletedTreatmentCoronary Artery Disease / Hypertensive1
4CompletedTreatmentDiabetes Mellitus (DM) / Hypertensive1
4CompletedTreatmentDiabetes Mellitus (DM) / Type 2 Diabetes Mellitus1
4CompletedTreatmentEssential Hypertension ( Mild to Moderate)1
4CompletedTreatmentHigh Blood Pressure1
4CompletedTreatmentHypertension, Dyslypidaemia1
4CompletedTreatmentHypertensive33
4CompletedTreatmentHypertensive / Impaired Renal Function1
4CompletedTreatmentHypertensive / Left Ventricle Hypertrophy1
4CompletedTreatmentHypertensive / Metabolic Syndromes2
4CompletedTreatmentHypertensive / Metabolic Syndromes / Obesity, Abdominal1
4CompletedTreatmentHypertensive / Pharmacogenetics1
4CompletedTreatmentHypertensive / Type 2 Diabetes Mellitus3
4CompletedTreatmentHypokalaemia1
4CompletedTreatmentStage 2 Systolic Hypertension1
4CompletedTreatmentStage II Hypertension1
4Not Yet RecruitingTreatmentChronic Kidney Disease (CKD)2
4Not Yet RecruitingTreatmentHypertension,Essential1
4Not Yet RecruitingTreatmentHypertensive1
4Not Yet RecruitingTreatmentType 2 Diabetes Mellitus1
4RecruitingBasic ScienceFeeling Anxious / Hypertensive1
4RecruitingPreventionBlood Pressures / Hypertensive / Strokes1
4RecruitingTreatmentBlood Pressure, High1
4RecruitingTreatmentCerebral Small Vessels Disease1
4RecruitingTreatmentHeart Failure, Unspecified1
4RecruitingTreatmentHypertensive1
4SuspendedTreatmentEnd Stage Renal Disease (ESRD) / Hypertensive / Proteinuria1
4Unknown StatusPreventionDiabetic Nephropathies1
4Unknown StatusTreatmentBlood Pressures1
4Unknown StatusTreatmentChronic Kidney Insufficiency / Diuresis Preserved / Hemodialysis Treatment1
4Unknown StatusTreatmentHypertension, Resistant to Conventional Therapy / Hypertension,Essential1
4Unknown StatusTreatmentHypertensive4
4Unknown StatusTreatmentLipotoxicity / Metabolic Syndromes1
4WithdrawnTreatmentHypertensive3
4WithdrawnTreatmentHypertensive / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableAging / Hypertensive1
Not AvailableCompletedNot AvailableCardiovascular Disease (CVD) / Heart Diseases / Hypertensive1
Not AvailableCompletedNot AvailableHealthy Normotensive Participants3
Not AvailableCompletedNot AvailableHealthy Volunteers4
Not AvailableCompletedNot AvailableHypertension,Essential1
Not AvailableCompletedNot AvailableHypertensive9
Not AvailableCompletedDiagnosticGitelman's syndrome1
Not AvailableCompletedDiagnosticHypertensive1
Not AvailableCompletedTreatmentAlbuminuria / Diabetes Mellitus (DM) / Endothelial Dysfunction1
Not AvailableCompletedTreatmentHypertension Treatment / Hypertension, Grade 1 / Hypertensive / N of 1 Study Design1
Not AvailableCompletedTreatmentHypertension,Essential1
Not AvailableCompletedTreatmentHypertensive8
Not AvailableCompletedTreatmentHypertensive / Plasma Renin Activity1
Not AvailableCompletedTreatmentHypertensive / Type 2 Diabetes Mellitus1
Not AvailableCompletedTreatmentNephrogenic Diabetes Insipidus1
Not AvailableCompletedTreatmentNocturia1
Not AvailableCompletedTreatmentType 2 Diabetes Mellitus / Vascular Diseases1
Not AvailableNot Yet RecruitingPreventionAging / Hypertensive / Sedentary Lifestyle1
Not AvailableRecruitingNot AvailableHypertension,Essential1
Not AvailableRecruitingDiagnosticArterial Hypertension1
Not AvailableRecruitingPreventionChronic Kidney Disease (CKD) / Hyperparathyroidism, Secondary1
Not AvailableRecruitingPreventionRenal Stones1
Not AvailableRecruitingTreatmentCritical Care / Fluid Shifts1
Not AvailableTerminatedPreventionMetabolic Syndromes1
Not AvailableTerminatedTreatmentHypertensive / Microvascular Angina1
Not AvailableUnknown StatusNot AvailableArterial Hypertension / Diabetes Mellitus (DM)1

Pharmacoeconomics

Manufacturers
  • Apotex inc
  • Aurobindo pharma ltd
  • Cadista pharmaceuticals inc
  • Ipca laboratories ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Unichem laboratories ltd
  • Vintage pharmaceuticals inc
  • West ward pharmaceutical corp
  • Watson laboratories inc
  • Morton grove pharmaceuticals inc
  • Roxane laboratories inc
  • Novartis pharmaceuticals corp
  • Abc holding corp
  • Actavis elizabeth llc
  • Alra laboratories inc
  • Ascot hosp pharmaceuticals inc div travenol laboratories inc
  • Barr laboratories inc
  • Caraco pharmaceutical laboratories ltd
  • Dava pharmaceuticals inc
  • Elkins sinn div ah robins co inc
  • Excellium pharmaceutical inc
  • Heather drug co inc
  • Heritage pharmaceuticals inc
  • Impax laboratories inc
  • Inwood laboratories inc sub forest laboratories inc
  • Lannett holdings inc
  • Mm mast and co
  • Mutual pharmaceutical co inc
  • Private formulations inc
  • Sandoz inc
  • Solvay pharmaceuticals
  • Superpharm corp
  • Teva pharmaceuticals usa inc
  • Tg united labs llc
  • Usl pharma inc
  • Vangard laboratories inc div midway medical co
  • Warner chilcott div warner lambert co
  • Whiteworth towne paulsen inc
  • Halsey drug co inc
  • Merck and co inc
  • Abbott laboratories pharmaceutical products div
Packagers
Dosage forms
FormRouteStrength
Tablet, film coatedOral
TabletOral50 mg
TabletOral12.5 mg
Tablet, coatedOral
CapsuleOral12.5 mg/1
Capsule, gelatin coatedOral12.5 mg/1
TabletOral12.5 mg/1
TabletOral25 mg/25mg
TabletOral25 mg/1
TabletOral50 mg/1
TabletOral50 mg/50mg
TabletOral25 mg
TabletOral100 mg
TabletOral
CapsuleOral
Prices
Unit descriptionCostUnit
Niferex-150 Forte 100 80-70 mg capsule Box109.86USD box
Niferex 100 mg/5ml Elixir 236ml Bottle80.55USD bottle
Niferex 100 40-20 mg capsule Box77.99USD box
Capozide 50-25 mg tablet3.63USD tablet
Ziac 10-6.25 mg tablet3.6USD tablet
Ziac 2.5-6.25 mg tablet3.6USD tablet
Ziac 5-6.25 mg tablet3.6USD tablet
Capozide 50-15 tablet3.49USD tablet
Capozide 50-25 tablet3.49USD tablet
Capozide 50-15 mg tablet2.59USD tablet
Lotensin 20 mg tablet2.25USD tablet
Lotensin 10 mg tablet2.09USD tablet
Lotensin 40 mg tablet2.09USD tablet
Lotensin 5 mg tablet2.09USD tablet
Accuretic 20-12.5 mg tablet2.04USD tablet
Capozide 25-15 tablet2.03USD tablet
Capozide 25-25 tablet2.03USD tablet
Accuretic 10-12.5 mg tablet2.0USD tablet
Accuretic 20-25 mg tablet2.0USD tablet
Lotensin HCT 20-12.5 mg tablet1.97USD tablet
Lotensin HCT 10-12.5 mg tablet1.95USD tablet
Lotensin HCT 20-25 mg tablet1.94USD tablet
Lotensin hct 10-12.5 tablet1.9USD tablet
Lotensin hct 20-12.5 tablet1.9USD tablet
Lotensin hct 20-25 tablet1.9USD tablet
Lotensin hct 5-6.25 tablet1.9USD tablet
Niferex-150 150-50-50 mg capsule1.62USD capsule
Capozide 25-15 mg tablet1.51USD tablet
Lotensin HCT 5-6.25 mg tablet1.31USD tablet
Hydrochlorothiazide powder1.1USD g
Hydrochlorothiazide 12.5 mg tablet0.82USD tablet
Moduretic 5-50 mg tablet0.68USD tablet
Hydrochlorothiazide 12.5 mg capsule0.5USD capsule
Hydrochlorothiazide 50 mg tablet0.16USD tablet
Apo-Hydro 100 mg Tablet0.13USD tablet
Hydrochlorothiazide 25 mg tablet0.11USD tablet
Apo-Hydro 50 mg Tablet0.06USD tablet
Novo-Hydrazide 50 mg Tablet0.06USD tablet
Apo-Hydro 25 mg Tablet0.04USD tablet
Novo-Hydrazide 25 mg Tablet0.04USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6294197Yes1997-12-182017-12-18Us
US6358986No2000-01-102020-01-10Us
US5559111Yes1999-01-212019-01-21Us
US5616599Yes1996-10-252016-10-25Us
US8618172No2008-07-132028-07-13Us
US6878703Yes2002-05-192022-05-19Us
US8101599No2003-05-162023-05-16Us
US8475839Yes2003-11-162023-11-16Us
US8618174No2001-11-152021-11-15Us
US8183295No2003-05-162023-05-16Us
US5994348Yes1995-12-072015-12-07Us
US9023893No2002-03-032022-03-03Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)266-268U.S. Patent 3,163,645.
water solubility722 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP-0.07HANSCH,C ET AL. (1995)
logS-2.62ADME Research, USCD
Caco2 permeability-6.06ADME Research, USCD
pKa7.9SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility2.24 mg/mLALOGPS
logP-0.16ALOGPS
logP-0.58ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)9.09ChemAxon
pKa (Strongest Basic)-2.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area118.36 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity63.11 m3·mol-1ChemAxon
Polarizability25.35 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9202
Blood Brain Barrier-0.9659
Caco-2 permeable-0.8956
P-glycoprotein substrateNon-substrate0.6533
P-glycoprotein inhibitor INon-inhibitor0.8624
P-glycoprotein inhibitor IINon-inhibitor0.8688
Renal organic cation transporterNon-inhibitor0.8416
CYP450 2C9 substrateNon-substrate0.7664
CYP450 2D6 substrateNon-substrate0.8333
CYP450 3A4 substrateNon-substrate0.6217
CYP450 1A2 substrateNon-inhibitor0.9401
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9252
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9569
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9036
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.7986
BiodegradationNot ready biodegradable0.9964
Rat acute toxicity2.0666 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9576
hERG inhibition (predictor II)Non-inhibitor0.9135
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (11.5 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-00r2-6490000000-3f5d9320308b823c6489
MS/MS Spectrum - Quattro_QQQ 10V, PositiveLC-MS/MSsplash10-052b-0090000000-aaa48e4702874457ae26
MS/MS Spectrum - Quattro_QQQ 25V, PositiveLC-MS/MSsplash10-0r6r-0920000000-b129acf72e7dde12441e
MS/MS Spectrum - Quattro_QQQ 40V, PositiveLC-MS/MSsplash10-0a4i-1900000000-67f803f38aed0bd12ade
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014i-0090000000-7906a6e4cfb51dce1396
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0002-0090000000-c44dbed5084dc5df03d8
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0002-0090000000-976dcb246a2272b22565
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0uxr-1090000000-16e563e592e4a566424d
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0fb9-9580000000-3c9227e3df8ed6dc9ae9
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-9720000000-12525bfcb83ea1611970
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-9200000000-df37b796b59f084b0229
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0002-0090000000-220666bc28231ad387e8
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0002-0090000000-f434c5d8ee94540ec0d2
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0uxr-1090000000-8a3c270e0fb285b26f15
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0fb9-9480000000-5f6c5ed1d291d71a0aae
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-9520000000-679def33e8239c1382f3
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-9400000000-c9b80274d62fda64c531
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014i-0090000000-0a962453b9e31eec3822
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0002-0090000000-ac2b5d07eaacba87a181
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0gb9-1090000000-8649018477d708cb6bd7
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-004i-9400000000-266cd4efe3deeebe29f3
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-014i-0090000000-bc85dd2515151e4fec03
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0090000000-f8a0765b6023cbf47593
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0090000000-ca679180c1ca0c54141e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0090000000-5aee0df6931c521ae675
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0390000000-2d94b79cdd59fb180851
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0f79-0920000000-a3852b5fd8f817191c39
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-017f1f0aa88d206d3790
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-05br-1900000000-9adb8f34fa45627894bb
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0090000000-49e6e4b4d7de4164fea3
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0090000000-eba848023908f7d51e1a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0490000000-09360a196ae79b28c238
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0f79-0920000000-f620823c599998180372
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-1900000000-bb4b565d2cab86e56d75
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-052r-2900000000-67c9a5ba10fd79140b7d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0090000000-de56ae9572cecd0e3bce
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-00lr-0090000000-6ec2b0c4b0ea116fd154
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001i-0490000000-86abfe4bae6e32f1189a
1H NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1,2,4-benzothiadiazine-1,1-dioxides. These are aromatic heterocyclic compounds containing a 1,2,4-benzothiadiazine ring system with two S=O bonds at the 1-position.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Thiadiazines
Sub Class
Benzothiadiazines
Direct Parent
1,2,4-benzothiadiazine-1,1-dioxides
Alternative Parents
Secondary alkylarylamines / Organosulfonamides / Benzenoids / Aryl chlorides / Aminosulfonyl compounds / Azacyclic compounds / Organopnictogen compounds / Organochlorides / Organic oxides / Hydrocarbon derivatives
Substituents
1,2,4-benzothiadiazine-1,1-dioxide / Secondary aliphatic/aromatic amine / Aryl chloride / Aryl halide / Organosulfonic acid amide / Benzenoid / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Aminosulfonyl compound / Sulfonyl
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
sulfonamide, organochlorine compound, benzothiadiazine (CHEBI:5778)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Key mediator of sodium and chloride reabsorption in this nephron segment, accounting for a significant fraction of renal sodium reabsorption.
Gene Name
SLC12A3
Uniprot ID
P55017
Uniprot Name
Solute carrier family 12 member 3
Molecular Weight
113138.04 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Ran XW, Wang C, Dai F, Jiang JJ, Tong NW, Li XJ, Liang JZ: [A case of Gitelman's syndrome presenting with severe hypocalcaemia and hypokalemic periodic paralysis]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 Jul;36(4):583-7. [PubMed:16078592]
  3. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E: WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic. Hypertension. 2005 Oct;46(4):758-65. Epub 2005 Sep 19. [PubMed:16172412]
  4. Abuladze N, Yanagawa N, Lee I, Jo OD, Newman D, Hwang J, Uyemura K, Pushkin A, Modlin RL, Kurtz I: Peripheral blood mononuclear cells express mutated NCCT mRNA in Gitelman's syndrome: evidence for abnormal thiazide-sensitive NaCl cotransport. J Am Soc Nephrol. 1998 May;9(5):819-26. [PubMed:9596079]
  5. Barry EL, Gesek FA, Kaplan MR, Hebert SC, Friedman PA: Expression of the sodium-chloride cotransporter in osteoblast-like cells: effect of thiazide diuretics. Am J Physiol. 1997 Jan;272(1 Pt 1):C109-16. [PubMed:9038817]
  6. Kurschat C, Heering P, Grabensee B: [Gitelman's syndrome: an important differential diagnosis of hypokalemia]. Dtsch Med Wochenschr. 2003 May 30;128(22):1225-8. [PubMed:12772080]
  7. Monroy A, Plata C, Hebert SC, Gamba G: Characterization of the thiazide-sensitive Na(+)-Cl(-) cotransporter: a new model for ions and diuretics interaction. Am J Physiol Renal Physiol. 2000 Jul;279(1):F161-9. [PubMed:10894798]
Details
2. Carbonic anhydrase 1
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name
CA1
Uniprot ID
P00915
Uniprot Name
Carbonic anhydrase 1
Molecular Weight
28870.0 Da
References
  1. Puscas I, Coltau M, Baican M, Domuta G, Hecht A: Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res. 1999;25(6):271-9. [PubMed:10713865]
  2. Couloigner V, Loiseau A, Sterkers O, Amiel C, Ferrary E: Effect of locally applied drugs on the endolymphatic sac potential. Laryngoscope. 1998 Apr;108(4 Pt 1):592-8. [PubMed:9546276]
  3. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014]
Details
3. Carbonic anhydrase 2
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion in...
Gene Name
CA2
Uniprot ID
P00918
Uniprot Name
Carbonic anhydrase 2
Molecular Weight
29245.895 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Meyerson LR, Nesta D: [3H]acetazolamide binding to carbonic anhydrase in normal and transformed cells. Biochem Pharmacol. 1991 Mar 15-Apr 1;41(6-7):995-1000. [PubMed:1901209]
  4. Schaeffer P, Vigne P, Frelin C, Lazdunski M: Identification and pharmacological properties of binding sites for the atypical thiazide diuretic, indapamide. Eur J Pharmacol. 1990 Jul 17;182(3):503-8. [PubMed:2226620]
  5. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014]
Details
4. Carbonic anhydrase 4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina an...
Gene Name
CA4
Uniprot ID
P22748
Uniprot Name
Carbonic anhydrase 4
Molecular Weight
35032.075 Da
References
  1. Puscas I, Coltau M, Baican M, Domuta G, Hecht A: Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res. 1999;25(6):271-9. [PubMed:10713865]
  2. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014]
Details
5. Carbonic anhydrase 9
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. Participates in pH regulation. May be involved in the control of cell proliferation and transformation. Appears to be a novel specific biomarker for a cervic...
Gene Name
CA9
Uniprot ID
Q16790
Uniprot Name
Carbonic anhydrase 9
Molecular Weight
49697.36 Da
References
  1. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014]
Details
6. Carbonic anhydrase 12
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide.
Gene Name
CA12
Uniprot ID
O43570
Uniprot Name
Carbonic anhydrase 12
Molecular Weight
39450.615 Da
References
  1. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Voltage-gated potassium channel activity
Specific Function
Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+). It is also activated by the concentration of cytosolic Mg(2+). Its activati...
Gene Name
KCNMA1
Uniprot ID
Q12791
Uniprot Name
Calcium-activated potassium channel subunit alpha-1
Molecular Weight
137558.115 Da
References
  1. Tricarico D, Barbieri M, Mele A, Carbonara G, Camerino DC: Carbonic anhydrase inhibitors are specific openers of skeletal muscle BK channel of K+-deficient rats. FASEB J. 2004 Apr;18(6):760-1. Epub 2004 Feb 6. [PubMed:14766795]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Race JE, Grassl SM, Williams WJ, Holtzman EJ: Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3). Biochem Biophys Res Commun. 1999 Feb 16;255(2):508-14. [PubMed:10049739]
  2. Uwai Y, Saito H, Hashimoto Y, Inui KI: Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Exp Ther. 2000 Oct;295(1):261-5. [PubMed:10991988]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34